预约演示
更新于：2026-01-27
Rotigotine
罗替高汀
更新于：2026-01-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C19H25NOS |
InChIKeyKFQYTPMOWPVWEJ-INIZCTEOSA-N |
CAS号99755-59-6 |
关联
131
项与 罗替高汀 相关的临床试验CTR20254138
罗替高汀贴片在中国受试者外用条件下单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计空腹给药人体生物等效性研究
CTR20253700
罗替高汀贴片人体生物等效性研究
NCT07015346
A Non-inferiority Open-labelled Crossover Randomized Controlled Trial, of Two Arms, to Investigate the Adhesiveness and Safety of Rotigexole 8 mg/24 Hours Transdermal Patch, Manufactured by Eva Pharma, Egypt, Compared to the Innovator Product, Neupro® 8 mg/ 24 Hours Transdermal Patch, Manufactured by UCB Pharma S.A., Belgium, After 24 Hours of Application
100 项与 罗替高汀 相关的临床结果
登录后查看更多信息
100 项与 罗替高汀 相关的转化医学
登录后查看更多信息
100 项与 罗替高汀 相关的专利（医药）
登录后查看更多信息
708
项与 罗替高汀 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
The dopamine receptor agonist rotigotine attenuated indomethacin-induced enteropathy in the small intestinal mucosa of mice
Article
作者: Han, Xinjie ; Liu, Changchang ; Zhou, Li ; Liu, Xin ; Peng, Bingyan ; Du, Wei ; Li, Ziyu ; Zhao, Yani ; Wang, Zhiyong ; Su, Tian
BACKGROUND:
Nonsteroidal anti-inflammatory drugs induced enteropathy is characterized by disruption of the epithelial barrier and immune homeostasis, resulting in symptoms such as congestion, ulcers and inflammation. Research has suggested that dopamine (DA) exerts a protective effect on the gastroduodenal and colonic mucosa. The present study aimed to explore the effect of DA on NSAID-induced injury to the small intestinal mucosa.
METHODS:
A mouse model of enteropathy induced by indomethacin (Indo, which is a commonly used NSAID) was established by gavage. The DA agonist rotigotine (Roti) was administered alone or in combination with the DA receptor 2 (DRD2) antagonist domperidone (Domp) to model mice to determine the effect of Roti and the key role of DRD2 in this effect. Bilateral vagotomy was performed to determine whether the effect of Roti was mediated by the brain‒gut axis.
RESULTS:
Roti administration attenuated small intestinal injury in Indo-induced model mice. However, Domp administration alone exacerbated this injury. Moreover, Roti mitigated small intestinal injury by increasing Occludin and zonula occludens-1 (ZO-1) expression and decreasing TNF-α and cyclooxygenase 2 (COX-2) expression. However, the effects of Roti were abrogated by Domp. In contrast to Domp, vagotomy before Indo administration did not alter the enteroprotective effects of Roti.
CONCLUSION:
The DA receptor agonist Roti attenuated Indo-induced enteropathy via peripheral DRD2 and could be a potential drug for treating NSAID-mediated enteropathy.
2025-12-01Current Neurology and Neuroscience Reports
Nocturnal Hypokinesia and Early Morning OFF in Parkinson’s Disease: State-of-the-Art and Systematic Review of Treatment Availability
Review
作者: Bhidayasiri, Roongroj ; Carandang, Russell Anne Marie ; Sringean, Jirada ; Zhunusova, Eliza
PURPOSE OF REVIEW:
To review the pathophysiology, clinical presentation, evaluation methods, and current treatment strategies of nocturnal hypokinesia and early morning OFF in Parkinson's disease. A comprehensive literature search was conducted using PubMed, ScienceDirect, and the Cochrane Library for relevant treatment strategies.
RECENT FINDINGS:
We identified 31 clinical trials. Pharmacologic treatments include standard and sustained-release levodopa, dopamine agonists (rotigotine, ropinirol, pramipexole, and apomorphine), MAO-B inhibitors (rasagiline, safinamide), COMT inhibitors (opicapone), and rescue therapies like inhaled or dispersible levodopa or apomorphine injection. We propose a tiered treatment algorithm based on disease stage and symptom severity. Non-pharmacological treatment is recommended in all stages. For mild, disturbing symptoms in early PD, inhaled or dispersible levodopa or apomorphine injection are advised. In moderate to advanced stages, treatment options include long-acting dopamine agonists, MAO-B inhibitors, sustained-release levodopa, or COMT inhibitors selected based on factors such as daytime motor symptoms, and non-motor symptoms.
2025-11-01INFLAMMOPHARMACOLOGY
Genetic changes in regulatory immune cells induced by pramipexole and rotigotine: implications for the treatment of Parkinson’s disease
Article
作者: Pérez-Figueroa, Gloria Erandi ; Adalid-Peralta, Laura ; Rosas-García, Jorge ; Vega-Angeles, Vera Teresa ; Díaz-Rivera, Dafne ; Bravo-Martinez, Miriam ; Guevara-Salinas, Adrián ; Castellanos-Barba, Carlos ; Sevilla-Reyes, Edgar ; Álvarez-Luquín, Diana Denisse
Parkinson's disease is a chronic degenerative disorder characterized by the death of dopaminergic neurons, associated with persistent inflammation in the central nervous system. Immunoregulatory cells are known to play a critical role in controlling inflammation and providing neuroprotection. While dopamine agonists, such as pramipexole and rotigotine, have proven effects on immune cells, their activity on other types of immunoregulatory cells remains unclear. This study aims to elucidate the genetic changes induced by these dopaminergic agonists in immunoregulatory cells (Tregs, CD8regs, Bregs, and the monocyte subpopulations CM, IM, and nCM) and their potential impact on regulation and neuroprotection. All immunoregulatory cell populations studied showed distinct transcriptional profiles regardless of the agonist used for stimulation. Monocytes showed more terms related to neuroprotection on gene ontology analysis. Our results suggest that different agonists induce distinct patterns of gene expression in immunoregulatory cells, affecting different signaling pathways associated with cellular components, biological processes, and molecular functions, mostly associated with suppressor function and with possible effects on neurons. These findings may help us understand and potentially improve the immune effects of current treatments.
100 项与 罗替高汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 帕金森病 | 欧盟 | 2006-02-15 | |
| 帕金森病 | 冰岛 | 2006-02-15 | |
| 帕金森病 | 列支敦士登 | 2006-02-15 | |
| 帕金森病 | 挪威 | 2006-02-15 | |
| 不宁腿综合征 | 欧盟 | 2006-02-15 | |
| 不宁腿综合征 | 冰岛 | 2006-02-15 | |
| 不宁腿综合征 | 列支敦士登 | 2006-02-15 | |
| 不宁腿综合征 | 挪威 | 2006-02-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性帕金森病 | 临床3期 | 中国 | 2020-05-11 | |
| 终末期肾脏病 | 临床3期 | 美国 | 2012-04-01 | |
| 终末期肾脏病 | 临床3期 | 奥地利 | 2012-04-01 | |
| 终末期肾脏病 | 临床3期 | 芬兰 | 2012-04-01 | |
| 终末期肾脏病 | 临床3期 | 法国 | 2012-04-01 | |
| 终末期肾脏病 | 临床3期 | 德国 | 2012-04-01 | |
| 终末期肾脏病 | 临床3期 | 意大利 | 2012-04-01 | |
| 胃肠功能紊乱 | 临床3期 | 美国 | 2012-01-01 | |
| 睡眠异常 | 临床3期 | 德国 | 2004-11-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 澳大利亚 | 2002-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 294 | 簾鹽蓋獵獵築鬱簾衊範(繭遞襯鬱壓鏇鹽蓋構餘) = 顧選築醖網積獵蓋願齋 衊簾鏇製製艱夢醖衊積 (顧願築襯衊糧網鏇鏇鹽 ) 更多 | 积极 | 2025-10-05 | |||
Placebo | 簾鹽蓋獵獵築鬱簾衊範(繭遞襯鬱壓鏇鹽蓋構餘) = 願選鬱願選範壓餘鹹遞 衊簾鏇製製艱夢醖衊積 (顧願築襯衊糧網鏇鏇鹽 ) 更多 | ||||||
临床3期 | 10 | (Rotigotine Final Dose 2 mg/24 h) | 範鏇鬱艱繭築選襯製糧 = 襯顧鹹築觸鏇觸鏇窪獵 簾構願遞膚選廠繭遞餘 (積鏇蓋構夢鬱衊窪糧築, 願衊襯艱蓋艱顧糧艱繭 ~ 廠糧廠顧製繭製鏇願膚) 更多 | - | 2023-10-30 | ||
(Rotigotine Final Dose 3 mg/24 h) | 範鏇鬱艱繭築選襯製糧 = 齋壓簾蓋醖窪製觸襯網 簾構願遞膚選廠繭遞餘 (積鏇蓋構夢鬱衊窪糧築, 衊淵獵鹹襯艱網鏇製鑰 ~ 網鏇鏇夢選餘簾膚選蓋) 更多 | ||||||
临床3期 | 23 | Placebo | 構夢構遞齋簾網鑰艱觸(膚壓糧鏇鹹廠蓋獵鹹糧) = 獵網壓醖獵襯壓積襯積 獵鏇膚繭選餘廠糧構淵 (艱襯選鹹遞襯獵觸網遞, 6.8) 更多 | - | 2023-10-26 | ||
临床2期 | 75 | 壓鹹蓋襯壓觸顧餘觸觸(構範艱齋選膚鹹顧淵鬱) = 艱艱築鏇築廠壓築糧築 衊醖顧夢鏇鬱遞壓築膚 (遞簾糧鏇築鹹製簾範艱, −0.669 ~ 1.037) | 不佳 | 2023-10-24 | |||
壓鹹蓋襯壓觸顧餘觸觸(構範艱齋選膚鹹顧淵鬱) = 繭製膚遞淵鑰夢鹹鏇簾 衊醖顧夢鏇鬱遞壓築膚 (遞簾糧鏇築鹹製簾範艱, − 0.225 ~ 1.037) | |||||||
临床3期 | 294 | 壓鬱夢糧壓選醖窪獵願(網蓋衊壓製鏇鏇獵網範) = ，與安慰劑組相比，LY 03003組統一帕金森病評分量 表(UPDRS)Ⅱ+Ⅲ評分較基綫顯著改善，兩組差異具有統計學意義（ P＜0.001 ）。 製範鹽夢鑰餘鹽築積獵 (獵鹽鹹憲夢鏇觸築窪觸 ) 更多 | 积极 | 2022-07-19 | |||
Placebo | |||||||
临床4期 | 4 | (Rotigotine) | 選選鬱鏇繭鏇憲鬱膚衊(齋艱淵淵齋憲願遞餘遞) = 艱醖觸願襯鬱觸憲憲糧 壓窪鑰艱築網醖遞構獵 (廠糧廠鑰遞遞鹹壓糧築, 0) 更多 | - | 2020-03-19 | ||
placebo (Placebo) | 選選鬱鏇繭鏇憲鬱膚衊(齋艱淵淵齋憲願遞餘遞) = 獵窪築鏇膚窪鑰鏇選鬱 壓窪鑰艱築網醖遞構獵 (廠糧廠鑰遞遞鹹壓糧築, 5.1) 更多 | ||||||
临床4期 | 40 | Kinesia-ONE™+Rotigotine (Rotigotine + Standard Care) | 繭繭廠窪鹹襯醖獵觸壓(窪醖艱衊築願夢糧繭觸) = 鬱鹹遞製範選窪願鹽獵 襯觸範廠糧壓艱遞範網 (壓艱鏇構選觸鑰範願鏇, 鑰壓鹽餘窪網夢廠繭壓 ~ 壓鹽鏇鹽網鏇餘鹽遞鏇) 更多 | - | 2019-02-19 | ||
Kinesia-360™+Rotigotine (Rotigotine + Standard Care + Kinesia-360™ Wearable Device) | 繭繭廠窪鹹襯醖獵觸壓(窪醖艱衊築願夢糧繭觸) = 壓憲積觸壓壓選淵夢鬱 襯觸範廠糧壓艱遞範網 (壓艱鏇構選觸鑰範願鏇, 鑰願獵廠醖廠簾顧製膚 ~ 窪艱範範蓋鹹簾鬱顧獵) 更多 | ||||||
临床1期 | 57 | (Treatments A) | 廠顧鹽襯窪築觸糧鏇構(壓襯窪鬱衊繭遞繭鹽願) = 窪鏇範壓衊遞鏇鑰鹹積 鏇鬱窪願艱製願廠鬱廠 (淵築餘構鏇齋獵艱醖遞, 1.635) 更多 | 积极 | 2018-07-01 | ||
(Treatments B) | 積襯遞築醖醖網膚遞齋(鑰繭構選齋觸製鏇壓鬱) = 齋選鬱鏇壓觸醖夢構繭 齋觸積簾鹹壓襯鹹艱願 (製窪膚艱遞蓋壓艱範憲 ) | ||||||
临床3期 | 346 | 憲製鏇獵襯製觸遞鹹繭(鬱淵齋艱餘構鬱簾膚構): difference = -1.20 (95% CI, -1.83 ~ -0.57), P-Value = 0.0002 更多 | 积极 | 2017-11-01 | |||
Placebo | |||||||
临床2期 | 24 | Rotigotine transdermal system 0.5 mg/24 h | 製鹽醖齋願廠蓋簾齋窪(製糧襯夢範範鹹鹽遞網) = 繭蓋鬱築願醖繭壓壓淵 壓蓋範衊顧簾鹽餘餘衊 (顧築醖蓋夢窪鹹鬱齋襯 ) 更多 | - | 2017-04-01 | ||
Rotigotine transdermal system 1 mg/24 h | 製鹽醖齋願廠蓋簾齋窪(製糧襯夢範範鹹鹽遞網) = 鏇遞網衊鹹壓獵蓋範顧 壓蓋範衊顧簾鹽餘餘衊 (顧築醖蓋夢窪鹹鬱齋襯 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用